FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, particularly a composition for treating cancer, wherein cancer involves a solid tumour that overexpresses FGFR2IIIb. Disclosed is afucosylated FGFR2IIIb antibody, a host cell for expression of said antibody. Disclosed is a method of producing said antibody, a method of treating cancer using said antibody.
EFFECT: invention has the ability effectively treat cancer associated with overexpression of FGFR2IIIb.
77 cl, 11 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AFUCOSYLATED FIBROBLAST GROWTH FACTOR FGFR2IIIB RECEPTOR | 2014 |
|
RU2740714C2 |
| FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN TREATING CANCER | 2016 |
|
RU2834309C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| ANTIBODIES TO FGFR2 IN COMBINATION WITH CHEMOTHERAPY IN CANCER TREATMENT | 2018 |
|
RU2797560C2 |
| COMBINED THERAPY BASED ON AFUCOSYLATED CD20 ANTIBODY IN COMBINATION WITH CD22 ANTIBODY CONJUGATE - DRUG PREPARATION | 2014 |
|
RU2700092C2 |
| MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2 | 2009 |
|
RU2546254C9 |
| COMBINATION THERAPY OF AFUCOSYLATED CD20 ANTIBODY WITH CD79b ANTIBODY-DRUGS CONJUGATE | 2014 |
|
RU2670971C9 |
| NOVEL ANTI-FGFR2B ANTIBODIES | 2020 |
|
RU2841589C1 |
| NOVEL ANTI-FGFR2B ANTIBODIES | 2020 |
|
RU2840536C1 |
| NOVEL ANTI-FGFR2B ANTIBODIES | 2020 |
|
RU2840537C1 |
